ArticleBMC cancer2020

Study protocol for an open-label, single-arm, phase Ib/II study of combination of toripalimab, nab-paclitaxel, and gemcitabine as the first-line treatment for patients with unresectable pancreatic ductal adenocarcinoma.

Lin Shui et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.